These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12048351)

  • 21. Antitumor activity of interleukin-18 against the murine T-cell leukemia/lymphoma EL-4 in syngeneic mice.
    Akamatsu S; Arai N; Hanaya T; Arai S; Tanimoto T; Fujii M; Kohno K; Micallef MJ; Ikeda M; Kurimoto M
    J Immunother; 2002; 25 Suppl 1():S28-34. PubMed ID: 12048348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.
    Feeley BT; Liu NQ; Conduah AH; Krenek L; Roth K; Dougall WC; Huard J; Dubinett S; Lieberman JR
    J Bone Miner Res; 2006 Oct; 21(10):1571-80. PubMed ID: 16995812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice.
    Miki T; Yano S; Hanibuchi M; Sone S
    Oncol Res; 2000; 12(5):209-17. PubMed ID: 11417746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
    Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
    PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.
    Bendre MS; Montague DC; Peery T; Akel NS; Gaddy D; Suva LJ
    Bone; 2003 Jul; 33(1):28-37. PubMed ID: 12919697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.
    Chantry AD; Heath D; Mulivor AW; Pearsall S; Baud'huin M; Coulton L; Evans H; Abdul N; Werner ED; Bouxsein ML; Key ML; Seehra J; Arnett TR; Vanderkerken K; Croucher P
    J Bone Miner Res; 2010 Dec; 25(12):2633-46. PubMed ID: 20533325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity.
    Yamada N; Niwa S; Tsujimura T; Iwasaki T; Sugihara A; Futani H; Hayashi S; Okamura H; Akedo H; Terada N
    Bone; 2002 Jun; 30(6):901-8. PubMed ID: 12052461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
    Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
    Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone resorption induced by a metastatic human melanoma cell line.
    Hiraga T; Nakajima T; Ozawa H
    Bone; 1995 Mar; 16(3):349-56. PubMed ID: 7786638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of bisphosphonate (pamidronate) on bone resorption resulting from metastasis of a squamous cell carcinoma: report of an autopsy case and evaluation of bone resorbing activity in an experimental animal model.
    Hiraga T; Takada M; Nakajima T; Ozawa H
    J Oral Maxillofac Surg; 1996 Nov; 54(11):1327-33. PubMed ID: 8941184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.
    Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ
    Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer cell-depleted SCID mice.
    Miki T; Yano S; Hanibuchi M; Kanematsu T; Muguruma H; Sone S
    Int J Cancer; 2004 Feb; 108(4):511-5. PubMed ID: 14696114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
    Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
    Miller RE; Jones JC; Tometsko M; Blake ML; Dougall WC
    J Thorac Oncol; 2014 Mar; 9(3):345-54. PubMed ID: 24496001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of cellular mechanisms of tumor osteolysis.
    Clohisy DR; Perkins SL; Ramnaraine ML
    Clin Orthop Relat Res; 2000 Apr; (373):104-14. PubMed ID: 10810467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.
    Winding B; NicAmhlaoibh R; Misander H; Høegh-Andersen P; Andersen TL; Holst-Hansen C; Heegaard AM; Foged NT; Brünner N; Delaissé JM
    Clin Cancer Res; 2002 Jun; 8(6):1932-9. PubMed ID: 12060638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
    Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
    Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.